ViroGates A/S (CPH:VIRO)

Market Cap	93.75M +22.2%
Revenue (ttm)	9.36M -0.4%
Net Income	-7.57M
EPS	-0.82
Shares Out	9.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Open	10.10
Previous Close	11.10
Day's Range	10.10 - 10.10
52-Week Range	9.05 - 17.40
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About ViroGates

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2025, ViroGates's revenue was 8.90 million, an increase of 24.67% compared to the previous year's 7.14 million. Losses were -10.40 million, -27.52% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error